

Regd. Office :-
330, TRIVIA Complex, Natubhai Circle,
Racecourse, Vadodara – 390007, Gujarat, INDIA
Phone : +91 265 2988903 / 2984803
Website : www.chemcrux.com
Email : girishshah@chemcrux.com



To
BSE LIMITED
Department of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400 001

11th February 2025

Dear Sir/Madam

Subject: Integrated Filing (Financial) for the quarter ended on 31st December, 2024

Ref: **BSE Scrip ID:** CHEMCRUX **BSE Scrip Code:** 540395

In terms of regulation 10(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in compliance with SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 dated 2nd January, 2025, please find enclosed herewith Integrated Filing (Financial) for the quarter ended 31st December 2024.

The above information is also available on the website of the Company at www.chemcrux.com.

Please take the same on record.

Thanking you

For CHEMCRUX ENTERPRISES LIMITED

Dipika Rajpal
Company Secretary & Compliance Officer

Encl.: As Above

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

To,
The Board of Directors,
Chemcrux Enterprises Limited,

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Chemcrux Enterprises Limited ('the Company') for the **quarter and nine months ended 31st December 2024** ('the Statement') attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations')

This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2012 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, together with the Notes thereon and read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Naresh & Co.
Chartered Accountants
FRN: 106928W

CA Harin Parikh
Partner

M.No. 107606

UDIN: 25107606BMOJCV3694

Place: Vadodara

Date: 11th February, 2025



CHEMCRUX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

UNAUDITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2024

(All amounts are in INR Lacs, Unless otherwise stated)

	Particulars	Quarter Ended			Period Ended		Year ended
		31-12-2024 Unaudited	30-09-2024 Unaudited	31-12-2023 Unaudited	31-12-2024 Unaudited	31-12-2023 Unaudited	31-03-2024 Audited
I.	Revenue from operations	1,942.36	1,775.62	2,180.65	5,428.83	5,992.84	7,846.53
II.	Other income	60.55	25.90	56.41	125.22	98.85	133.55
III.	Total Income (I+II)	2,002.91	1,801.52	2,237.06	5,554.06	6,091.69	7,980.07
IV.	Expenses:						
	Cost of materials consumed	869.45	741.46	580.73	2,308.88	1,739.11	2,533.25
	Purchase of Traded Goods			-			-
	Changes in inventories of finished goods, by-products and work in progress	(60.10)	(36.95)	361.76	(48.62)	733.22	579.79
	Employee benefits expense	217.48	211.27	205.77	634.09	681.54	882.91
	Finance costs	59.60	32.79	17.36	105.55	70.24	83.24
	Depreciation and amortization expense	92.09	73.47	57.78	221.59	173.48	228.52
	Other expenses	646.08	623.88	594.29	1,822.54	1,780.33	2,529.21
	Total expenses (IV)	1,824.61	1,645.91	1,817.70	5,044.04	5,177.91	6,836.92
V.	Profit Before Tax	178.30	155.61	419.36	510.02	913.77	1,143.15
VIII.	Tax expense :						
	Current tax	27.04	-	115.40	72.34	234.81	285.00
	Deferred tax	19.59	40.86	6.53	67.44	24.47	11.89
	Income tax relating to earlier years	(1.17)	-	31.29	(1.17)	-	1.83
		45.46	40.86	153.22	138.61	259.29	298.72
IX.	Profit for the period	132.84	114.75	266.14	371.41	654.49	844.43
X	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss						
	- Defined Benefit Plan	3.47	(9.33)	8.96	7.30	24.91	(45.09)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.87	(2.35)	2.26	1.84	6.27	(11.35)
	(iii) Items that will be reclassified to profit or loss						
	-Fair Value Gain on Investments	11.85	39.24	32.23	87.01	94.46	133.65
	(iv) Income tax relating to items that will be reclassified to profit or loss	2.98	9.88	8.11	21.90	23.77	33.64
	Total other comprehensive income, net of tax	11.46	22.38	30.83	70.57	52.05	66.27
XI.	Total comprehensive income for the period	144.30	137.13	296.96	441.98	706.53	910.70
XII.	Earnings per equity share (Nominal value per share Rs. 10/-)						
	- Basic (Rs.)	0.90	0.77	1.80	2.51	4.42	5.70
	- Diluted (Rs.)	0.90	0.77	1.80	2.51	4.42	5.70




Notes to Standalone Financial Results :

- 1 The above financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 2 The above financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 11th February, 2025.
- 3 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of ind AS 108, on Operating Segment, constitute a single operating segment.
- 4 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

**For & on behalf of the Board
Chemcrux Enterprises Limited**


Girishkumar Shah
Whole Time Director
DIN : 00469291



Place : Vadodara
Date : 11th February, 2025

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

To,
The Board of Directors,
Chemcrux Enterprises Limited,

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Chemcrux Enterprises Limited** ('the Company') and its Joint Venture ('Kalichem Private Limited') for the **quarter and nine months ended 31st December 2024** ('the Statement'), being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').

This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above and based on the consideration of the limited review report of Joint Venture's Auditor referred in below paragraph, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, together with the Notes thereon and read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Other Matters :

Reference is Invited to Note No. 5 to the Statement. The Joint Venture commenced commercial production during the quarter - on 26th November 2024. The Joint Venture has incurred total losses of ₹35.07 lakh for quarter i.e. from date of commencement till 31st December, 2024. As a co-venturer holding 50% equity in the Joint Venture, the Company's share of said loss of the amounts to ₹17.53 lakh. However, since the cost of total investment of the Company in the Joint Venture till end of the quarter is ₹0.50 lakh only, it has recognized the loss the extent of ₹0.50 lakh only, i.e. to the extent of investment, in accordance with Ind AS 28.

We did not review the standalone financial results of the Joint Venture. These financial results have been reviewed by other auditor whose review reports have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the Joint Venture is based solely on the reports of the other auditor.

Our Conclusion is not modified in respect of the above Other Matters

For Naresh & Co
Chartered Accountants
FRN: 106928W

CA Harin Parikh
Partner

M. No. 107606

UDIN: 25107606BMOJCW7010

Place: Vadodara

Date: 11th February, 2025



CHEMCRIX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2024

(All amounts are in INR Lacs, Unless otherwise stated)

	Particulars	Quarter Ended			Period Ended		Year ended
		31-12-2024 Unaudited	30-09-2024 Unaudited	31-12-2023 Unaudited	31-12-2024 Unaudited	31-12-2023 Unaudited	31-03-2024 Audited
I.	Revenue from operations	1,942.36	1,775.62	2,180.65	5,428.83	5,992.84	7,846.53
II.	Other income	60.55	25.90	56.41	125.22	98.85	133.55
III.	Total Income (I+II)	2,002.91	1,801.52	2,237.06	5,554.06	6,091.69	7,980.07
IV.	Expenses:						
	Cost of materials consumed	869.45	741.46	580.73	2,308.88	1,739.11	2,533.25
	Purchase of Traded Goods						
	Changes in inventories of finished goods, by-products and work in progress	(60.10)	(36.95)	361.76	(48.62)	733.22	579.79
	Employee benefits expense	217.48	211.27	205.77	634.09	681.54	882.91
	Finance costs	59.60	32.79	17.36	105.55	70.24	83.24
	Depreciation and amortization expense	92.09	73.47	57.78	221.59	173.48	228.52
	Other expenses	646.08	623.88	594.29	1,822.54	1,780.33	2,529.21
V.	Total expenses (IV)	1,824.61	1,645.91	1,817.70	5,044.04	5,177.91	6,836.92
VI.	Profit Before Share in profit of Joint Venture (III-IV)	178.30	155.61	419.36	510.02	913.77	1,143.15
VII.	Share in Profit/(Loss) of Joint Venture (Net of Tax)	(0.50)	-	-	-	-	-
VIII.	Profit Before Tax	177.80	155.61	419.36	510.02	913.77	1,143.15
IX.	Tax expense :						
	Current tax	27.04	-	115.40	72.34	234.81	285.00
	Deferred tax	19.59	40.86	6.53	67.44	24.47	11.89
	Income tax relating to earlier years	(1.17)	-	31.29	(1.17)	-	1.83
		45.46	40.86	153.22	138.61	259.29	298.72
X.	Profit for the period	132.34	114.75	266.14	371.41	654.49	844.43
XI.	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss						
	- Defined Benefit Plan	3.47	(9.33)	8.96	7.30	(24.91)	(45.09)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.87	(2.35)	2.26	1.84	(6.27)	(11.35)
	(iii) Items that will be reclassified to profit or loss						
	-Fair Value Gain on Investments	11.85	39.24	32.23	87.01	94.46	133.65
	(iv) Income tax relating to items that will be reclassified to profit or loss	2.98	9.88	8.11	21.90	23.77	33.64
	Total other comprehensive income, net of tax	11.46	22.38	30.83	70.57	52.05	66.27
XII.	Total comprehensive income for the period	143.80	137.13	296.96	441.98	706.53	910.70
XIII.	Earnings per equity share (Nominal value per share Rs. 10/-)						
	- Basic (Rs.)	0.89	0.77	1.80	2.51	4.42	5.70
	- Diluted (Rs.)	0.89	0.77	1.80	2.51	4.42	5.70



Notes to Consolidated Financial Results :


- 1 List of Entities Consolidated included in the Statement.

Name of the Joint Venture

Kalichem Private Limited

- 2 The above financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 3 The Company does not have any Subsidiaries. The Company has Consolidated the Financial Results of the Joint Venture under the Equity Method.
- 4 The Financial Statements of the Joint Venture for the quarter and nine month period ended 31st December, 2024 have been subjected to Limited Review by their Independent Statutory Auditors who have furnished their Unmodified Opinion on the same in the Limited Review Report dtd. 31st January, 2025.
- 5 The Joint Venture commenced commercial production during the quarter - on 26th November 2024. The Joint Venture has incurred total losses of ₹35.07 lakh for quarter i.e. from date of commencement till 31st December, 2024. As an co-venturer holding 50% equity in the Joint Venture, the share of said loss of the Company amounts to ₹17.53 lakh. However, since the cost of total investment of the Company in the Joint Venture till end of the quarter is ₹0.50 lakh only, it has recognized the loss the extent of ₹0.50 lakh only, i.e. to the extent of investment, in accordance with Ind AS 28.
- 6 The above financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 11th February, 2025.
- 7 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of ind AS 108, on Operating Segment, constitute a single operating segment.
- 8 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

For & on behalf of the Board
Chemcrux Enterprises Limited


Girishkumar Shah
Whole Time Director
DIN : 00469291



Place : Vadodara
Date : 11th February, 2025

Regd. Office :-
330, TRIVIA Complex, Natubhai Circle,
Racecourse, Vadodara – 390007, Gujarat, INDIA
Phone : +91 265 2988903 / 2984803
Website : www.chemcrux.com
Email : girishshah@chemcrux.com



- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. – NOT APPLICABLE**
- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – NOT APPLICABLE**
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – NOT APPLICABLE**
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) – NOT APPLICABLE**

Factory

4712-14, GIDC, Road South - 10, Ankleshwar - 393002 (Gujarat) India.
Ph.: +91 2646 221427, 239737 | Email : sanjay@chemcrux.com